ItalyItaly

Sigma-Tau buys specialty pharmaceuticals from Enzon

12.11.2009

Rome - Sigma-Tau SpA will acquire the specialty pharmaceuticals business of Enzon Pharmaceuticals Inc for $300 million in cash and up to $27 million in potential milestones. Enzon’s specialty pharmaceutical business includes four marketed products: Abelcet, an antifungal amphotericin B liposomal injection, Adagen, an enzyme replacement therapy to treat severe combined immunodeficiency disease (SCID), and two cancer drugs, Oncaspar pegaspargase and DepoCyt Ara-C. The purchase also includes Enzon's manufacturing facility in Indianapolis, Indiana, which will be taken over by a US subsidiary of Sigma-Tau Pharmaceuticals, Inc. Enzon will receive royalties of 5 to 10 percent on incremental net sales of the four products above a 2009 baseline amount from Enzon’s four marketed specialty pharmaceutical products up to 2014. The transaction could be deemed to constitute a sale of “substantially all” of Enzon’s assets under Delaware law, and is therefore contingent upon approval by the holders of a majority of Enzon’s outstanding shares of common stock.
With this deal Sigma-Tau hopes to gain a better presence in the US market and to increase its standing in the field of rare diseases. The wholly Italian -owned company is based in Pomezia, near Rome. In 2008, the company achieved a turnover of €613 million. The company says a total of 13 NCEs and 12 known molecular entities in 33 different indications are currently at various stages of development. A number of these are aimed at rare diseases. Therapeutic areas in which the company's research and development are focused include metabolism, neurology, cardiovascular, oncology and immunology.

ItalyItaly

07.03.2012

Toscana Biomarkers S.r.l has entered the market for biomarkers with its first diagnostic kit. In late January, the company from Siena signed a licence agreement with DIESSE Ricerche S.r.l, based in Genoa. DIESSE will produce and...

ItalyItaly

07.03.2012

Italian researchers have reprogrammed neonatal cardiomyocytes into iPSCs that can re-differentiate toward CMs more efficiently than either cardiac fibroblast-derived iPS cells or even ES cells. (Cell Death Differ.,...

ItalyItaly

09.01.2012

Rome – A cold virus isolated from chimpanzees might work as an vector for human vaccines. Adenoviruses are principally suitable as vectors for vaccines for their ability to induce strong immune responses. But as most humans have...

ItalyItaly

16.12.2011

Milan/Turku – Italian drug developer Newron SpA has had a roller-coaster ride in the last few months. First Merck Serono decided to drop its stake in the company’s Parkinson’s Disease candidate salfinamide, and returned the...

ItalyItaly

15.12.2011

Genoa/Irvine – Researchers from the universities at Genoa and Irvine (US) have patented a new compound that blocks removal of the endo­cannabinoid painkiller anandamide from the synaptic space by a selective transport system....

ItalyItaly

01.10.2011

Parma/Baranzate – Chiesi Farmaceutici Spa has said it will lengthen its long-term collaboration with NiKem Research, which is focused on developing treatments within the respiratory therapeutic area. The two drug developers have...

ItalyItaly

01.10.2011

Milan/Turku – Biotie Therapies ASA’s announcement that it had signed an agreement to acquire Newron Pharma­ceuticals S.p.A. for €45m is both good and bad news for the Italian biotechnology sector. While Italy is losing one of its...

ItalyItaly

19.08.2011

Como – Shares in Gentium SpA lost about a third of their value on Thursday after The Italian biopharmaceutical company withdrew a marketing application for its drug Defibrotide being used against complications related to stem...

ItalyItaly

01.08.2011

Milan/London – Italy’s MolMed SpA has signed a deal with UK-based pharmaceutical giant GlaxoSmithKline to develop a production process for a gene therapy against the rare ‘bubble boy disease’. Over the next two years, GSK will...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-italy/article/sigma-tau-buys-specialty-pharmaceuticals-from-enzon.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%
  • ADDEX4.00 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%

TOP

  • SANTHERA82.95 CHF20.4%
  • LONZA101.10 CHF6.1%
  • MAGFORCE6.50 EUR5.7%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.10 EUR-24.5%
  • VITA 343.96 EUR-18.4%

TOP

  • SANTHERA82.95 CHF3758.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR195.2%

FLOP

  • CYTOS0.26 CHF-93.6%
  • MEDIGENE4.65 EUR-68.1%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 22.08.2014


Current issue

All issues

Product of the week

Products